Genetic Control Directed toward Spontaneous IFN-α/IFN-β Responses and Downstream IFN-γ Expression Influences the Pathogenesis of a Murine Psoriasis-Like Skin Disease1

Psoriasis is an inflammatory skin disease, onset and severity of which are controlled by multiple genetic factors; aberrant expression of and responses to several cytokines including IFN-α/IFN-β and IFN-γ are associated with this “type 1” disease. However, it remains unclear whether genetic regulation influences these cytokine-related abnormalities. Mice deficient for IFN regulatory factor-2 (IRF-2) on the C57BL/6 background (IRF-2−/−BN mice) exhibited accelerated IFN-α/IFN-β responses leading to a psoriasis-like skin inflammation. In this study, we found that this skin phenotype disappeared in IRF-2−/− mice with the BALB/c or BALB/c × C57BL/6 F1 backgrounds. Genome-wide scan revealed two major quantitative trait loci controlled the skin disease severity. Interestingly, these loci were different from that for the defect in CD4+ dendritic cells, another IFN-α/IFN-β-dependent phenotype of the mice. Notably, IFN-γ expression as well as spontaneous IFN-α/IFN-β responses were up-regulated several fold spontaneously in the skin in IRF-2−/−BN mice but not in IRF-2−/− mice with “resistant” backgrounds. The absence of such IFN-γ up-regulation in IRF-2−/−BN mice lacking the IFN-α/IFN-β receptor or β2-microglobulin indicated that accelerated IFN-α/IFN-β signals augmented IFN-γ expression by CD8+ T cells in the skin. IFN-γ indeed played pathogenic roles as skin inflammation was delayed and was much more infrequent when IRF-2−/−BN mice lacked the IFN-γ receptor. Our current study thus revealed a novel genetic mechanism that kept the skin immune system under control and prevented skin inflammation through regulating the magnitude of IFN-α/IFN-β responses and downstream IFN-γ production, independently of CD4+ dendritic cells.

[1]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[2]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[3]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[4]  O. Boyman,et al.  The pathogenic role of tissue-resident immune cells in psoriasis. , 2007, Trends in immunology.

[5]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[6]  F. Nestle,et al.  Animal models of psoriasis: a brief update , 2006 .

[7]  M. Pasparakis,et al.  Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. , 2006, The Journal of clinical investigation.

[8]  N. Van Rooijen,et al.  Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. , 2006, The Journal of clinical investigation.

[9]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[10]  H. Young,et al.  Impaired Langerhans cell migration in psoriasis , 2006, The Journal of experimental medicine.

[11]  D. Tough,et al.  Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming1 , 2006, The Journal of Immunology.

[12]  F. Nestle,et al.  Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. , 2005, The Journal of investigative dermatology.

[13]  C. Geisler,et al.  Increased sensitivity to interferon-α in psoriatic T cells , 2005 .

[14]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[15]  Takashi Saito,et al.  Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance. , 2005, Blood.

[16]  E. Wagner,et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins , 2005, Nature.

[17]  A. Bowcock,et al.  Getting under the skin: the immunogenetics of psoriasis , 2005, Nature Reviews Immunology.

[18]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[19]  S. Hida,et al.  IFN Regulatory Factor-2 Deficiency Revealed a Novel Checkpoint Critical for the Generation of Peripheral NK Cells 1 , 2005, The Journal of Immunology.

[20]  A. Bowcock,et al.  Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.

[21]  A. Bowcock,et al.  The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. , 2004, Human molecular genetics.

[22]  S. Hida,et al.  Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Smedley,et al.  Variation at the IRF2 gene and susceptibility to psoriasis in chromosome 4q-linked families. , 2004, The Journal of investigative dermatology.

[24]  T. Kupper,et al.  Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.

[25]  K. Honda,et al.  Negative regulation of IFN-α/β signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells , 2004 .

[26]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[27]  P. Parren,et al.  Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. , 2003, The Journal of clinical investigation.

[28]  P. Borrow,et al.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.

[29]  S. Vogel,et al.  Regulation of Lipopolysaccharide Sensitivity by IFN Regulatory Factor-21 , 2003, The Journal of Immunology.

[30]  Wing Hung Wong,et al.  Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. , 2003, Physiological genomics.

[31]  G. Courtois,et al.  TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2 , 2002, Nature.

[32]  George Stark,et al.  Isolation and Characterization of a Human STAT1Gene Regulatory Element , 2002, The Journal of Biological Chemistry.

[33]  Yong‐jun Liu,et al.  Mouse and human dendritic cell subtypes , 2002, Nature Reviews Immunology.

[34]  F. Belardelli,et al.  IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation1 , 2001, The Journal of Immunology.

[35]  J. Ovigne,et al.  Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon‐gamma , 2001, Experimental dermatology.

[36]  T. Taniguchi,et al.  CD8 (+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-α/β signaling , 2000 .

[37]  X. Lens,et al.  Secondary hyperparathyroidism exacerbation: a rare side-effect of interferon-alpha? , 1999, Clinical Nephrology.

[38]  M. Schön,et al.  Animal models of psoriasis - what can we learn from them? , 1999, The Journal of investigative dermatology.

[39]  H. Teh,et al.  Specific antiviral activity demonstrated by TGTP, a member of a new family of interferon-induced GTPases. , 1998, Journal of immunology.

[40]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[41]  S. Lessin,et al.  De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma. , 1995, Journal of the American Academy of Dermatology.

[42]  W. O'Brien,et al.  Molecular cloning and characterization of a murine LPS-inducible cDNA. , 1994, Journal of immunology.

[43]  W. Jochum,et al.  T cells involved in psoriasis vulgaris belong to the Th1 subset. , 1994, The Journal of investigative dermatology.

[44]  E. Schrumpf,et al.  Psoriasis induced by interferon‐α , 1991 .

[45]  J. de Maeyer-Guignard,et al.  Interferon structural genes do not participate in quantitative regulation of interferon production by If loci as shown in C57BL/6 mice that are congenic with BALB/c mice at the alpha interferon gene cluster , 1986, Journal of virology.

[46]  A. Bowcock,et al.  Psoriasis: genetic associations and immune system changes , 2007, Genes and Immunity.

[47]  J. Clifford,et al.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model , 2005, Nature Medicine.

[48]  L. van der Fits,et al.  In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. , 2004, The Journal of investigative dermatology.

[49]  G. T. te Meerman,et al.  Evaluation of the IRF-2 gene as a candidate for PSORS3. , 2004, The Journal of investigative dermatology.

[50]  J. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents. , 2002, Journal of the American Academy of Dermatology.